| Bioactivity | BAY-218 (AHR antagonist 1) is an aryl hydrocarbon receptor (AHR) antagonist. BAY-218 has AHR inhibitory activity with an IC50 of 39.9 μM in in U87 glioblastoma cells. BAY-218 can be used for the research of cancer or conditions with dysregulated immune responses[1]. | ||||||||||||
| Target | IC50: 39.9 nM (AHR in human cell line) | ||||||||||||
| Invitro | BAY-218 (example 23) (72 pM-20 μM) has AHR inhibitory activity with an IC50 of 39.9 μM in in U87 glioblastoma cells[1].BAY-218 (1 nM-3 μM) has CYP1A1 inhibitory activity with an IC50 of 70.7 μM in human monocytic U937 cell line[1].BAY-218 (1 μM) reverses KA-induced inhibition of TNFα production by LPS stimulated human monocytes[1]. RT-PCR[1] Cell Line: | ||||||||||||
| In Vivo | BAY-218 (example 23) (p.o; 30 mg/kg; bid) has good anti-tumor effect combinated with aPD-L1[1]. Animal Model: | ||||||||||||
| Name | BAY-218 | ||||||||||||
| CAS | 2162982-11-6 | ||||||||||||
| Formula | C20H17ClFN3O3 | ||||||||||||
| Molar Mass | 401.82 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Norbert Schmees, et al. 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides. WO2017202816A1. |
BAY-218
CAS: 2162982-11-6 F: C20H17ClFN3O3 W: 401.82
BAY-218 (AHR antagonist 1) is an aryl hydrocarbon receptor (AHR) antagonist. BAY-218 has AHR inhibitory activity with an
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.